Merck Sharp & Dohme Corp. v. Albrecht Case Brief Summary | Law Case Explained
Get more case briefs explained with Quimbee. Quimbee has over 35,900 case briefs (and counting) keyed to 984 casebooks ► https://www.quimbee.com/case-briefs-overview Merck Sharp & Dohme Corp. v. Albrecht | 139 S. Ct. 1668 (2019) Under state law, manufacturers have a duty to warn consumers of risks associated with their products. In Merck Sharp and Dohme Corporation versus Albrecht, we’ll explore what’s required for federal regulation to preempt state tort duty. Merck Sharp and Dohme manufactured Fosamax, an osteoporosis drug. However, Fosamax had the potential to increase the risk of atypical femoral fractures, a rare bone stress fracture. When Fosamax was approved by the Food and Drug Administration, Fosamax’s label didn’t warn of this risk. Between nineteen ninety-nine and twenty ten, many who took Fosamax experienced atypical fractures. In two thousand eight, Merck’s application to add a general warning about the risk of stress fractures was rejected by the F D A. But given the building evidence of individuals experiencing the rare fracture, in twenty ten, the F D A ordered Merck to warn about atypical femoral fractures on its label. Over five hundred consumers, including Doris Albrecht, sued Merck in the United States District Court for the District of New Jersey, alleging that Merck failed its state law duty to warn. In a motion for summary judgment, Merck argued that, because the F D A rejected its warning application and would likely reject a future application, the state law claims were preempted by federal law. The district court granted Merck’s motion. Albrecht appealed to the Third Circuit, which, after applying a clear-evidence standard, vacated the district court’s judgment and remanded the case. The Third Circuit reasoned that whether the F D A would’ve rejected a proposed warning label was a question of fact that needed to be decided by a jury. Merck petitioned the United States Supreme Court for review, which granted cert. Want more details on this case? Get the rule of law, issues, holding and reasonings, and more case facts here: https://www.quimbee.com/cases/merck-sharp-amp-dohme-corp-v-albrecht The Quimbee App features over 16,300 case briefs keyed to 223 casebooks. Try it free for 7 days! ► https://www.quimbee.com/case-briefs-overview Have Questions about this Case? Submit your questions and get answers from a real attorney here: https://www.quimbee.com/cases/merck-sharp-amp-dohme-corp-v-albrecht Did we just become best friends? Stay connected to Quimbee here: Subscribe to our YouTube Channel ► https://www.youtube.com/subscription_center?add_user=QuimbeeDotCom Quimbee Case Brief App ► https://www.quimbee.com/case-briefs-overview Facebook ► https://www.facebook.com/quimbeedotcom/ Twitter ► https://twitter.com/quimbeedotcom #casebriefs #lawcases #casesummaries
Get more case briefs explained with Quimbee. Quimbee has over 35,900 case briefs (and counting) keyed to 984 casebooks ► https://www.quimbee.com/case-briefs-overview Merck Sharp & Dohme Corp. v. Albrecht | 139 S. Ct. 1668 (2019) Under state law, manufacturers have a duty to warn consumers of risks associated with their products. In Merck Sharp and Dohme Corporation versus Albrecht, we’ll explore what’s required for federal regulation to preempt state tort duty. Merck Sharp and Dohme manufactured Fosamax, an osteoporosis drug. However, Fosamax had the potential to increase the risk of atypical femoral fractures, a rare bone stress fracture. When Fosamax was approved by the Food and Drug Administration, Fosamax’s label didn’t warn of this risk. Between nineteen ninety-nine and twenty ten, many who took Fosamax experienced atypical fractures. In two thousand eight, Merck’s application to add a general warning about the risk of stress fractures was rejected by the F D A. But given the building evidence of individuals experiencing the rare fracture, in twenty ten, the F D A ordered Merck to warn about atypical femoral fractures on its label. Over five hundred consumers, including Doris Albrecht, sued Merck in the United States District Court for the District of New Jersey, alleging that Merck failed its state law duty to warn. In a motion for summary judgment, Merck argued that, because the F D A rejected its warning application and would likely reject a future application, the state law claims were preempted by federal law. The district court granted Merck’s motion. Albrecht appealed to the Third Circuit, which, after applying a clear-evidence standard, vacated the district court’s judgment and remanded the case. The Third Circuit reasoned that whether the F D A would’ve rejected a proposed warning label was a question of fact that needed to be decided by a jury. Merck petitioned the United States Supreme Court for review, which granted cert. Want more details on this case? Get the rule of law, issues, holding and reasonings, and more case facts here: https://www.quimbee.com/cases/merck-sharp-amp-dohme-corp-v-albrecht The Quimbee App features over 16,300 case briefs keyed to 223 casebooks. Try it free for 7 days! ► https://www.quimbee.com/case-briefs-overview Have Questions about this Case? Submit your questions and get answers from a real attorney here: https://www.quimbee.com/cases/merck-sharp-amp-dohme-corp-v-albrecht Did we just become best friends? Stay connected to Quimbee here: Subscribe to our YouTube Channel ► https://www.youtube.com/subscription_center?add_user=QuimbeeDotCom Quimbee Case Brief App ► https://www.quimbee.com/case-briefs-overview Facebook ► https://www.facebook.com/quimbeedotcom/ Twitter ► https://twitter.com/quimbeedotcom #casebriefs #lawcases #casesummaries